Answers are grounded in this paper and cite their sources.
Parallel-group studies have established the efficacy of cholinesterase inhibitors in Alzheimer's disease, at least for short-term cognitive and clinical global enhancement. Noncognitive outcomes are currently under scrutiny. Time to reach clinical milestones may be a more useful trial design for new studies aiming to delay appearance or progression of disease.
No takes yet. Share an insight, caveat, or question.
Serge Gauthier (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: